FDA Clearance Tracker · K161508
Ceruloplasmin
Last checked: Nov 20, 2026Latest source record: Jan 9, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jan 9, 2017
Substantially Equivalent
Time to decision
222 days
Received Jun 1, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K161508
- Device name
- Ceruloplasmin
- Applicant
- Beckman Coulter Ireland, Inc.
- Applicant location
- Co. Clare, IE
- Received
- Jun 1, 2016
- Decided
- Jan 9, 2017
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5210
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code DDB. The earliest in FDA's data is K771795, decided Nov 14, 1977.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K161508
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Beckman Coulter Ireland, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- HbA1c Advanced510(k)
K182651 · Decided Jan 16, 2019 · 114 days after receipt
Device type: Hemoglobin A1c Test System (PDJ) · Laboratory Medicine & Pathology
- Beta-2-Microglobulin510(k)
K161297 · Decided Jun 7, 2016 · 29 days after receipt
Device type: System, Test, Beta-2-Microglobulin Immunological (JZG) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.